echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Cefoperazone Sodium and Sulbactam Sodium for Erye Pharmaceutical Injection Passed Consistency Evaluation of Generic Drugs

    Cefoperazone Sodium and Sulbactam Sodium for Erye Pharmaceutical Injection Passed Consistency Evaluation of Generic Drugs

    • Last Update: 2022-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On April 6, NMPA's official website showed that Suzhou Erye Pharmaceutical's cefoperazone sodium and sulbactam sodium for injection passed the consistency evaluation of generic drugs, making it the third company to pass the evaluation
    .
    Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
    .
     
    Cefoperazone sodium and sulbactam sodium for injection are mainly used to treat infections caused by sensitive bacteria, including respiratory tract infections (upper and lower respiratory tract), urinary tract infections (upper and lower urinary tract), peritonitis, cholecystitis, cholangitis and other intra-abdominal infections
    .
     
    According to data from Minet.
    com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
    .
     
    Sales of terminal cefoperazone-sulbactam in Chinese public medical institutions (unit: ten thousand yuan)
    Source: Minet.
    com China's public medical institutions terminal competition pattern
     
    Although 79 domestic companies have the production approval for cefoperazone sodium and sulbactam sodium for injection, and 19 companies have the production approval for cefoperazone sodium and sulbactam sodium for injection (2:1), the original manufacturer Pfizer has long dominated the cefoperazone and sulbactam market for a long time.

    .
     
      At present, only one company, Suzhou Dawnrays Pharmaceutical Co.
    , Ltd.
    , has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
    and Suzhou Erye Pharmaceutical
    .
     
      Data source: Minet database
      On April 6, NMPA's official website showed that Suzhou Erye Pharmaceutical's cefoperazone sodium and sulbactam sodium for injection passed the consistency evaluation of generic drugs, making it the third company to pass the evaluation
    .
    Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
    .
     
      Cefoperazone sodium and sulbactam sodium for injection are mainly used to treat infections caused by sensitive bacteria, including respiratory tract infections (upper and lower respiratory tract), urinary tract infections (upper and lower urinary tract), peritonitis, cholecystitis, cholangitis and other intra-abdominal infections
    .
     
      According to data from Minet.
    com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
    .
     
      Sales of terminal cefoperazone-sulbactam in Chinese public medical institutions (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      Although 79 domestic companies have the production approval for cefoperazone sodium and sulbactam sodium for injection, and 19 companies have the production approval for cefoperazone sodium and sulbactam sodium for injection (2:1), the original manufacturer Pfizer has long dominated the cefoperazone and sulbactam market for a long time.

    .
     
      At present, only one company, Suzhou Dawnrays Pharmaceutical Co.
    , Ltd.
    , has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
    and Suzhou Erye Pharmaceutical
    .
     
      Data source: Minet database
      On April 6, NMPA's official website showed that Suzhou Erye Pharmaceutical's cefoperazone sodium and sulbactam sodium for injection passed the consistency evaluation of generic drugs, making it the third company to pass the evaluation
    .
    Cefoperazone-sulbactam is a cephalosporin compound preparation, with terminal sales of over 6 billion yuan in Chinese public medical institutions in 2020
    .
     
      Cefoperazone sodium and sulbactam sodium for injection are mainly used to treat infections caused by sensitive bacteria, including respiratory tract infections (upper and lower respiratory tract), urinary tract infections (upper and lower urinary tract), peritonitis, cholecystitis, cholangitis and other intra-abdominal infections
    .
     
      According to data from Minet.
    com, in 2020, the sales of terminal cefoperazone and sulbactam in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan; in the first half of 2021, its sales The amount exceeds 3 billion yuan, and Pfizer occupies more than 80% of the market share
    .
    hospital hospital hospital
     
      Sales of terminal cefoperazone-sulbactam in Chinese public medical institutions (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      Although 79 domestic companies have the production approval for cefoperazone sodium and sulbactam sodium for injection, and 19 companies have the production approval for cefoperazone sodium and sulbactam sodium for injection (2:1), the original manufacturer Pfizer has long dominated the cefoperazone and sulbactam market for a long time.

    .
    enterprise enterprise enterprise
     
      At present, only one company, Suzhou Dawnrays Pharmaceutical Co.
    , Ltd.
    , has reviewed cefoperazone sodium and sulbactam sodium for injection (2:1); three companies have reviewed cefoperazone sodium and sulbactam sodium for injection, including Shandong Runze Pharmaceutical and Shenzhen Lijian Pharmaceutical.
    and Suzhou Erye Pharmaceutical
    .
     
      Data source: Minet database
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.